Design, Synthesis, and Evaluation of Novel Cinnamic Acid-tryptamine Hybrid for Inhibition of Acetylcholinesterase and Butyrylcholinesterase

Overview

Journal Daru

Specialty Pharmacology

Date 2020 May 7

PMID 32372339

Citations 6

Authors

Shahrzad Ghafary

Roshanak Ghobadian

Mohammad Mahdavi

Hamid Nadri

Alireza Moradi

Tahmineh Akbarzadeh

Zahra Najafi

Mohammad Sharifzadeh

Najmeh Edraki

Farshad Homayouni Moghadam

Mohsen Amini

Affiliations

Soon will be listed here.

Abstract

Background: Acetylcholine deficiencies in hippocampus and cortex, aggregation of β-amyloid, and β-secretase over activity have been introduced as main reasons in pathogenesis of Alzheimer's disease.

Methods: Colorimetric Ellman's method was used for determination of IC value in AChE and BChE inhibitory activity. The kinetic studies, neuroprotective and β-secretase inhibitory activities, evaluation of inhibitory potency on β-amyloid (Aβ) aggregations induced by AChE, and docking study were performed for prediction of the mechanism of action.

Result And Discussion: A new series of cinnamic acids-tryptamine hybrid was designed, synthesized, and evaluated as dual cholinesterase inhibitors. These compounds demonstrated in-vitro inhibitory activities against acetyl cholinesterase (AChE) and butyryl cholinesterase (BChE). Among of these synthesized compounds, (E)-N-(2-(1H-indol-3-yl)ethyl)-3-(3,4-dimethoxyphenyl)acrylamide (5q) demonstrated the most potent AChE inhibitory activity (IC = 11.51 μM) and (E)-N-(2-(1H-indol-3-yl)ethyl)-3-(2-chlorophenyl)acrylamide (5b) were the best anti-BChE (IC = 1.95 μM) compounds. In addition, the molecular modeling and kinetic studies depicted 5q and 5b were mixed type inhibitor and bound with both the peripheral anionic site (PAS) and catalytic sites (CAS) of AChE and BChE. Moreover, compound 5q showed mild neuroprotective in PC12 cell line and weak β-secretase inhibitory activities. This compound also inhibited aggregation of β-amyloid (Aβ) in self-induced peptide aggregation test at concentration of 10 μM.

Conclusion: It is worth noting that both the kinetic study and the molecular modeling of 5q and 5b depicted that these compounds simultaneously interacted with both the catalytic active site and the peripheral anionic site of AChE and BChE. These findings match with those resulted data from the enzyme inhibition assay. Graphical abstract A new series of cinnamic-derived acids-tryptamine hybrid derivatives were designed, synthesized and evaluated as butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) inhibitors and neuroprotective agents. Compound 5b and 5q, as the more potent compounds, interacted with both the peripheral site and the choline binding site having mixed type inhibition. Results suggested that derivatives have a therapeutic potential for the treatment of AD.

Citing Articles

Discovery of novel theophylline derivatives bearing tetrazole scaffold for the treatment of Alzheimer's disease.

Hung N, Quoc Tien L, Hai Linh V, Tran H, Nguyen T, Pham D RSC Adv. 2025; 15(9):6994-7003.

PMID: 40041377 PMC: 11877286. DOI: 10.1039/d5ra00488h.

Cinnamic acid conjugated with triazole acetamides as anti-Alzheimer and anti-melanogenesis candidates: an in vitro and in silico study.

Shokouhi Asl A, Sayahi M, Hashempur M, Irajie C, Alaeddini A, Ghafouri S Sci Rep. 2025; 15(1):655.

PMID: 39754023 PMC: 11698978. DOI: 10.1038/s41598-024-83020-3.

Cinnamic Acid Derivatives: Recent Discoveries and Development Strategies for Alzheimer's Disease.

Liu Y, Zhang Z, Zhu Z, Yang Y, Peng W, Chen Q Mini Rev Med Chem. 2024; 25(2):163-175.

PMID: 39219429 DOI: 10.2174/0113895575330648240819112435.

Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer's Disease.

Drakontaeidi A, Pontiki E Int J Mol Sci. 2024; 25(1).

PMID: 38203753 PMC: 10778916. DOI: 10.3390/ijms25010582.

Thiocarbohydrazone and Chalcone-Derived 3,4-Dihydropyrimidinethione as Lipid Peroxidation and Soybean Lipoxygenase Inhibitors.

Georgiou N, Chontzopoulou E, Cheilari A, Katsogiannou A, Karta D, Vavougyiou K ACS Omega. 2023; 8(13):11966-11977.

PMID: 37033811 PMC: 10077549. DOI: 10.1021/acsomega.2c07625.

References

Hariri R, Afshar Z, Mahdavi M, Safavi M, Saeedi M, Najafi Z . Novel Tacrine-Based Pyrano[3',4':5,6]pyrano[2,3-b]quinolinones: Synthesis and Cholinesterase Inhibitory Activity. Arch Pharm (Weinheim). 2016; 349(12):915-924. DOI: 10.1002/ardp.201600123. View

Ghanei-Nasab S, Khoobi M, Hadizadeh F, Marjani A, Moradi A, Nadri H . Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety. Eur J Med Chem. 2016; 121:40-46. DOI: 10.1016/j.ejmech.2016.05.014. View

Pietrzik C, Behl C . Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol. 2005; 86(3):173-85. PMC: 2517414. DOI: 10.1111/j.0959-9673.2005.00435.x. View

Khoobi M, Alipour M, Sakhteman A, Nadri H, Moradi A, Ghandi M . Design, synthesis, biological evaluation and docking study of 5-oxo-4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Eur J Med Chem. 2013; 68:260-9. DOI: 10.1016/j.ejmech.2013.07.038. View

Mohammadi-Khanaposhtani M, Mahdavi M, Saeedi M, Sabourian R, Safavi M, Khanavi M . Design, Synthesis, Biological Evaluation, and Docking Study of Acetylcholinesterase Inhibitors: New Acridone-1,2,4-oxadiazole-1,2,3-triazole Hybrids. Chem Biol Drug Des. 2015; 86(6):1425-32. DOI: 10.1111/cbdd.12609. View

Zhang X, He X, Chen Q, Lu J, Rapposelli S, Pi R . A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimer's disease. Bioorg Med Chem. 2018; 26(3):543-550. DOI: 10.1016/j.bmc.2017.12.042. View

Luo X, Wang C, Liu Y, Huang Z . New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease. Eur J Med Chem. 2015; 103:302-11. DOI: 10.1016/j.ejmech.2015.08.052. View

Bhakta H, Park C, Yokozawa T, Tanaka T, Jung H, Choi J . Potential anti-cholinesterase and β-site amyloid precursor protein cleaving enzyme 1 inhibitory activities of cornuside and gallotannins from Cornus officinalis fruits. Arch Pharm Res. 2017; 40(7):836-853. DOI: 10.1007/s12272-017-0924-z. View

Bartolini M, Bertucci C, Bolognesi M, Cavalli A, Melchiorre C, Andrisano V . Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem. 2007; 8(17):2152-61. DOI: 10.1002/cbic.200700427. View

10.

Reinke A, Gestwicki J . Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des. 2007; 70(3):206-15. DOI: 10.1111/j.1747-0285.2007.00557.x. View

11.

Baharloo F, Moslemin M, Nadri H, Asadipour A, Mahdavi M, Emami S . Benzofuran-derived benzylpyridinium bromides as potent acetylcholinesterase inhibitors. Eur J Med Chem. 2015; 93:196-201. DOI: 10.1016/j.ejmech.2015.02.009. View

12.

Watkins P, ZIMMERMAN H, KNAPP M, Gracon S, Lewis K . Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994; 271(13):992-8. View

13.

Ghobadian R, Mahdavi M, Nadri H, Moradi A, Edraki N, Akbarzadeh T . Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities. Eur J Med Chem. 2018; 155:49-60. DOI: 10.1016/j.ejmech.2018.05.031. View

14.

Estrada M, Herrera-Arozamena C, Perez C, Vina D, Romero A, Morales-Garcia J . New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. Eur J Med Chem. 2016; 121:376-386. DOI: 10.1016/j.ejmech.2016.05.055. View

15.

Najafi Z, Mahdavi M, Saeedi M, Karimpour-Razkenari E, Asatouri R, Vafadarnejad F . Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors. Eur J Med Chem. 2016; 125:1200-1212. DOI: 10.1016/j.ejmech.2016.11.008. View

16.

Saeed A, Mahesar P, Zaib S, Khan M, Matin A, Shahid M . Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases. Eur J Med Chem. 2014; 78:43-53. DOI: 10.1016/j.ejmech.2014.03.015. View

17.

Arab S, Sadat-Ebrahimi S, Mohammadi-Khanaposhtani M, Moradi A, Nadri H, Mahdavi M . Synthesis and Evaluation of Chroman-4-One Linked to N-Benzyl Pyridinium Derivatives as New Acetylcholinesterase Inhibitors. Arch Pharm (Weinheim). 2015; 348(9):643-9. DOI: 10.1002/ardp.201500149. View

18.

Mostofi M, Mohammadi Ziarani G, Mahdavi M, Moradi A, Nadri H, Emami S . Synthesis and structure-activity relationship study of benzofuran-based chalconoids bearing benzylpyridinium moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem. 2015; 103:361-9. DOI: 10.1016/j.ejmech.2015.08.061. View

19.

Mollazadeh M, Mohammadi-Khanaposhtani M, Zonouzi A, Nadri H, Najafi Z, Larijani B . New benzyl pyridinium derivatives bearing 2,4-dioxochroman moiety as potent agents for treatment of Alzheimer's disease: Design, synthesis, biological evaluation, and docking study. Bioorg Chem. 2019; 87:506-515. DOI: 10.1016/j.bioorg.2019.03.012. View

20.

Zha G, Zhang C, Qin H, Jantan I, Sher M, Amjad M . Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation. Bioorg Med Chem. 2016; 24(10):2352-9. DOI: 10.1016/j.bmc.2016.04.015. View